Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin

Página do item simplificado
dc.contributor.authorFuchs, Beth Burgwyn
dc.contributor.authorRajamuthiah, Rajmohan
dc.contributor.authorSouza, Ana Carolina Remondi
dc.contributor.authorEatemadpour, Soraya
dc.contributor.authorRossoni, Rodnei Dennis [UNESP]
dc.contributor.authorSantos, Daniel Assis
dc.contributor.authorJunqueira, Juliana C [UNESP]
dc.contributor.authorRice, Louis B
dc.contributor.authorMylonakis, Eleftherios
dc.contributor.institutionAlpert Medical School and Brown University
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversidade Federal de Minas Gerais (UFMG)
dc.date.accessioned2018-12-11T17:27:11Z
dc.date.available2018-12-11T17:27:11Z
dc.date.issued2016-02-01
dc.description.abstractBackground: We identified auranofin as an antimicrobial compound utilizing a high-throughput screen using a Caenorhabditis elegans-Staphylococcus aureus infection model. Results/methodology: Treatment of infected nematodes with auranofin resulted in a prolonged survival rate of 95%, reached with 0.78 μg/ml. Further investigation of the antimicrobial activity of auranofin found inhibition against S. aureus, Enterococcus faecium and Enterococcus faecalis. Importantly, the fungal pathogens Cryptococcus neoformans was also effectively inhibited with an MIC at 0.5 μg/ml. Auranofin appears to target the thioredoxin system. Conclusion: This work provides extensive additional data on the antibacterial effects of auranofin that includes both reference and clinical isolates and reports a novel inhibition of fungal pathogens by this compound.en
dc.description.affiliationRhode Island Hospital Alpert Medical School and Brown University
dc.description.affiliationEscola Paulista de Medicina Universidade Federal de São Paulo
dc.description.affiliationDepartment of Biosciences and Oral Diagnosis Univ Estadual Paulista/UNESP
dc.description.affiliationDepartment of Microbiology Instituto de Ciências Biológicas Universidade Federal de Minas Gerais
dc.description.affiliationUnespDepartment of Biosciences and Oral Diagnosis Univ Estadual Paulista/UNESP
dc.format.extent117-132
dc.identifierhttp://dx.doi.org/10.4155/fmc.15.182
dc.identifier.citationFuture Medicinal Chemistry, v. 8, n. 2, p. 117-132, 2016.
dc.identifier.doi10.4155/fmc.15.182
dc.identifier.issn1756-8927
dc.identifier.issn1756-8919
dc.identifier.scopus2-s2.0-84958050404
dc.identifier.urihttp://hdl.handle.net/11449/177804
dc.language.isoeng
dc.relation.ispartofFuture Medicinal Chemistry
dc.relation.ispartofsjr1,111
dc.relation.ispartofsjr1,111
dc.rights.accessRightsAcesso restrito
dc.sourceScopus
dc.subjectantimicrobial
dc.subjectauranofin
dc.subjectBucillus subtilis
dc.subjectCandida albicans
dc.subjectCryptococcus neoformans
dc.subjectEnterococcus faecalis
dc.subjectEnterococcus faecium
dc.subjectStaphylococcus aureus
dc.titleInhibition of bacterial and fungal pathogens by the orphaned drug auranofinen
dc.typeArtigo

Arquivos

Coleções

Artigos - Biociências e Diagnóstico Bucal - ICT